

Ho Sup Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/466486/publications.pdf>

Version: 2024-02-01

104
papers

653
citations

687363

13
h-index

839539

18
g-index

111
all docs

111
docs citations

111
times ranked

1255
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Correlation between Brain Natriuretic Peptide and Anthracyclin-induced Cardiac Toxicity. <i>Cancer Research and Treatment</i> , 2008, 40, 121.	3.0	45
2	Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286.	4.1	34
3	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
4	The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 43-49.	0.4	22
5	The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1820-1820.	1.4	19
6	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
7	Herpesviridae Viral Infections After Chemotherapy Without Antiviral Prophylaxis in Patients With Malignant Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 146-150.	1.3	17
8	High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 73-79.	2.0	17
9	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	2.6	17
10	Incidence Rates and Risk Factors for Vascular Events in Patients With Essential Thrombocythemia: A Multicenter Study From Korea. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 70-75.	0.4	16
11	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	1.3	16
12	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	1.8	16
13	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	1.8	16
14	Echinochrome A Promotes Ex Vivo Expansion of Peripheral Blood-Derived CD34+ Cells, Potentially through Downregulation of ROS Production and Activation of the Src-Lyn-p110 β Pathway. <i>Marine Drugs</i> , 2019, 17, 526.	4.6	15
15	Incidence of malignancy and related mortality after kidney transplantation: a nationwide, population-based cohort study in Korea. <i>Scientific Reports</i> , 2020, 10, 21398.	3.3	14
16	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156.	1.4	13
17	Phase II study of R \bar{a} CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
18	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
20	Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia. <i>BMC Cancer</i> , 2021, 21, 177.	2.6	11
21	Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. <i>Leukemia Research</i> , 2009, 33, 426-433.	0.8	10
22	R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma. <i>Blood Research</i> , 2014, 49, 107.	1.3	10
23	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
24	Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. <i>International Journal of Hematology</i> , 2020, 111, 559-566.	1.6	10
25	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
26	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	6.2	10
27	Predictive factors for rapid neutrophil and platelet engraftment after allogeneic peripheral blood stem cell transplantation in patients with acute leukemia. <i>Annals of Hematology</i> , 2013, 92, 1685-1693.	1.8	9
28	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
29	Synergistic Integration of Mesenchymal Stem Cells and Hydrostatic Pressure in the Expansion and Maintenance of Human Hematopoietic/Progenitor Cells. <i>Stem Cells International</i> , 2018, 2018, 1-12.	2.5	9
30	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	1.6	9
31	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP). <i>Journal of Internal Medicine</i> , 2016, 261, 164-174.	1.64	9
32	Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study. <i>BMC Cancer</i> , 2020, 20, 623.	2.6	9
33	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. <i>Leukemia Research</i> , 2017, 60, 135-144.	0.8	8
34	Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 809-819.	1.7	8
35	Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. <i>Experimental Hematology</i> , 2016, 44, 3-13.	0.4	7
36	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	1.6	7

#	ARTICLE	IF	CITATIONS
37	The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. <i>International Journal of Cancer</i> , 2019, 145, 2459-2467.	5.1	7
38	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. <i>Annals of Hematology</i> , 2020, 99, 223-228.	1.8	6
39	Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. <i>Scientific Reports</i> , 2020, 10, 11649.	3.3	6
40	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	1.8	6
41	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	1.8	6
42	Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study. <i>Cancer Research and Treatment</i> , 2014, 46, 331-338.	3.0	6
43	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	1.8	5
44	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	1.3	5
45	A case of bortezomib (Velcade)-induced Stevens-Johnson syndrome confirmed by patch test. <i>Asia Pacific Allergy</i> , 2021, 11, e17.	1.3	5
46	Prognostic Significance Of Systemic Inflammatory Factors In Patients With Diffuse Large B Cell Lymphoma Treated By R-CHOP. <i>Blood</i> , 2013, 122, 1802-1802.	1.4	5
47	Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2013, 28, 80.	2.5	4
48	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	4
49	The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. <i>Annals of Hematology</i> , 2016, 95, 911-919.	1.8	4
50	Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). <i>Annals of Hematology</i> , 2016, 95, 619-624.	1.8	4
51	Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 197-202.	0.4	4
52	Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. <i>Annals of Hematology</i> , 2018, 97, 2309-2317.	1.8	4
53	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. <i>Scientific Reports</i> , 2020, 10, 13359.	3.3	4
54	Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation. <i>Blood Research</i> , 2015, 50, 160.	1.3	3

#	ARTICLE	IF	CITATIONS
55	The risk factors associated with treatment-related mortality in 16,073 kidney transplantation: A nationwide cohort study. PLoS ONE, 2020, 15, e0236274.	2.5	3
56	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. Transplant International, 2020, 33, 1211-1219.	1.6	3
57	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. International Journal of Hematology, 2021, 113, 81-91.	1.6	3
58	Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget, 2017, 8, 79414-79424.	1.8	3
59	A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma. Annals of Laboratory Medicine, 2020, 40, 417-420.	2.5	3
60	Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. Korean Journal of Internal Medicine, 2020, 35, 429-437.	1.7	3
61	Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population. Scientific Reports, 2021, 11, 22907.	3.3	3
62	First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. Blood Research, 2019, 54, 151-153.	1.3	2
63	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2051-2059.	2.4	2
64	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. British Journal of Haematology, 2019, 186, e151-e155.	2.5	2
65	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 149-156.	0.4	2
66	Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report. Cancer Research and Treatment, 2011, 43, 199-203.	3.0	2
67	Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma. British Journal of Haematology, 2022, 196, 1117-1120.	2.5	2
68	A Retrospective Study to Evaluate the Survival Rates in R-CHOP Chemotherapy Followed by Autologous Stem Cell Transplantation for the Treatment of Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 4517-4517.	1.4	2
69	The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. Korean Journal of Internal Medicine, 2015, 30, 675-683.	1.7	2
70	Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide. Korean Journal of Internal Medicine, 2022, 37, 179-189.	1.7	2
71	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2022, 101, 1217-1226.	1.8	2
72	Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea. Blood Research, 2022, , .	1.3	2

#	ARTICLE	IF	CITATIONS
73	Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2016, 95, 1795-1804.	1.8	1
74	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e367-e373.	0.4	1
75	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
76	Nasal Type NK/T Cell Lymphoma with Cutaneous and Ocular Involvement: A Case Report.. <i>Blood</i> , 2007, 110, 4434-4434.	1.4	1
77	Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 1687-1687.	1.4	1
78	No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1194-1202.	1.7	1
79	Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer. <i>Kosin Medical Journal</i> , 2017, 32, 170.	0.3	0
80	Herpesviridae Viral Infections Following Chemotherapy in Patients with Lymphoma : Incidence, Risk Factors, and Prevention.. <i>Blood</i> , 2009, 114, 3704-3704.	1.4	0
81	Clinical Implications of Clonal Cytogenetic Abnormalities of Aquired Aplastic Anemia.. <i>Blood</i> , 2009, 114, 4217-4217.	1.4	0
82	Splenic Volume Can Be a Novel Predictive Parameter for the Prognosis of Chronic Lymphocytic Leukemia?. <i>Blood</i> , 2010, 116, 4623-4623.	1.4	0
83	Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including <i>Camphylobacter Jejuni</i> . <i>Blood</i> , 2011, 118, 5224-5224.	1.4	0
84	Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea. <i>Blood</i> , 2011, 118, 2021-2021.	1.4	0
85	High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. <i>Blood</i> , 2012, 120, 1917-1917.	1.4	0
86	Prognostic Significance of Elevated Serum Ferritin Before Chemotherapy in Patients with Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012, 120, 5099-5099.	1.4	0
87	Predictive Factors for Rapid Engraftment of Neutrophil and Platelet After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Hematologic Malignancies. <i>Blood</i> , 2012, 120, 4499-4499.	1.4	0
88	Role Of Hypomethylating Agents For Patients With Lower-Risk Myelodysplastic Syndrome Defined By IPSS and IPSS-R. <i>Blood</i> , 2013, 122, 2782-2782.	1.4	0
89	Efficacy and Safety of Deferasirox Estimated By Serum Ferritin and Labile Plasma Iron Levels in Patients with Aplastic Anemia, Myelodysplastic Syndrome, or Hematologic Malignancy with Transfusional Iron Overload. <i>Blood</i> , 2014, 124, 2676-2676.	1.4	0
90	Inferior Long-Term Outcome of Front-Line Hypomethylating Agent Compared to Supportive Care in Patients with Lower Risk Myelodysplastic Syndrome: Prosensity Score Matched Analysis. <i>Blood</i> , 2014, 124, 3255-3255.	1.4	0

#	ARTICLE	IF	CITATIONS
91	The Clinical Impact of Thalidomide Maintenance on Progression Free Survival and Postrelapse Survival after Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple myeloma. <i>Blood</i> , 2014, 124, 3975-3975.	1.4	0
92	The Prognostic Impact of Inflammatory Factors for Survival in Patients with Newly Diagnosed Multiple Myeloma Who Were Treated with Thalidomide Containing Induction Chemotherapy Underwent Autologous Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5896-5896.	1.4	0
93	Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Blood</i> , 2016, 128, 1811-1811.	1.4	0
94	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	1.4	0
95	The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19538-e19538.	1.6	0
96	Incidence, Prevalence, Mortality, and Causes of Death in Waldenström Macroglobulinemia in South Korea: A Nationwide, Population-Based Study. <i>Blood</i> , 2018, 132, 5654-5654.	1.4	0
97	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. <i>Blood</i> , 2018, 132, 3876-3876.	1.4	0
98	Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era. <i>Blood</i> , 2019, 134, 4002-4002.	1.4	0
99	Title is missing!. , 2020, 15, e0236274.		0
100	Title is missing!. , 2020, 15, e0236274.		0
101	Title is missing!. , 2020, 15, e0236274.		0
102	Title is missing!. , 2020, 15, e0236274.		0
103	Title is missing!. , 2020, 15, e0236274.		0
104	Title is missing!. , 2020, 15, e0236274.		0